




Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement



Annual Report and Accounts

31 March 2022

Company registration number 02908933 | Charity registration number 1040650



Charity Information	1
Trustees' Annual Report	2
Statement Of Directors' Responsibilities	8
Independent Examiner's Report	11
 Funds Statements:	
Statement Of Financial Activities	13
Statement Of Financial Activities - Prior Year Statement	14
Statement Of Total Recognised Gains And Losses	15
Movements In Funds	16
Revenue Funds	16
Income And Expenditure Account	18
Balance Sheet	19
 Notes To The Accounts	22



The Trustees present their Report and Accounts for the year ended 31 March 2022, which also comprises the Directors' Report required by the Companies Act 2006.

Charity Name

The legal name of the charity is: Bath Institute for Rheumatic Diseases.

The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered with the Charity Commission in England & Wales (CCEW) with charity number 1040650.

The charity does not operate in any overseas jurisdictions.

Legal structure of the Charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:

Department D1
Wolfson Building
Royal United Hospital
Bath
BA1 3NG

Telephone: 01225 336363

Email Address: BIRD@birdbath.org.uk

Web Address: www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in Office on the Date the Report was Approved were:

Dr N Hall (resigned 29th April 2021)
Mr C Johns (Chair)
Ms S Lear (resigned 15th March 2022)
Dr A Mackenzie
Prof N McHugh
Prof B Morley (appointed 25th May 2021)
Dr J Pauling (resigned 15th March 2022)
Dr R Sengupta
Mr J Sherwin
Dr W Tillett



Objects and Activities of the Charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Response to the continuing Covid pandemic and economic climate

The Covid 19 pandemic continued to shape BIRD's operations during the period covered by this report. Most live events (patient engagement days and Education seminars for Healthcare Professionals, also the annual fundraising/awareness raising event) were cancelled and the office was closed. Consultant Trustees and other healthcare professionals on BIRD's committees, undertaking research and acting as podcast and webinar speakers were extremely busy addressing the backlog in patients.

The education programme for consultants, GPs, nurses and physiotherapists was also partly delivered online. And staff continued to work mainly from home.

We finish the financial year £117,000 ahead of last year on total funds. Income was up by a third, due to fundraising efforts, and expenditure was reduced to 80% of previous year mainly because of an unintended reduction in grant giving (being dependent on the quality of grant applications we receive, not all make it through the approval process). There was also an exceptional credit item of £41,895 in the accounts, which represents a cancelled project grant and an underspend in a grant from a previous year. The growth in the value of our investments grew by £132,320.

Grants awarded for Research

BIRD funds research projects in rheumatic diseases which:

- Help to promote and advance medical knowledge
- Improve treatments for patients

- Encourage collaboration between clinicians and research scientists
- Supports the next generation of researchers into bone and joint diseases

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

Recent evaluation of BIRD's research grant programme since 2016 confirmed that it has achieved its intended functions of promoting and advancing medical science, pump-priming research, helping researchers in the early stages of their careers, helping clinicians to be research active, encouraging collaborations between clinicians and research scientists, and ensuring patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded over 20 projects, with at least 20 published academic papers and 537 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

In total, £55,047 was awarded:

- **£14,695** to Dr Anita McGrogan and Dr Rachel Charlton for research into medication use during pregnancy and pregnancy outcomes in women with chronic inflammatory disease.
- **£19,766** to Dr William Tillet for research into identifying support needs for rheumatology patients following COVID-19 shielding.
- **£17,950** to Dr Sarah Tansley for researching novel biomarkers in Juvenile Dermatomyositis.
- **£2082** to Dr Sarah Tansley as the final instalment




in her National Institute for Health Research Clinical Lectureship.

- **£554** in bursaries for two clinicians, Dr Ben Mulhearn, Academic clinical fellow in Rheumatology and Jade Skeates, Rheumatology Physiotherapy Team Lead, to attend the British Society for Rheumatology conference in Glasgow, as part of a new BIRD bursary scheme to help early career stage specialists take up research.

BIRD took forward the first phase of recommendations from the previous year's research grant evaluation report by:

- Introducing a light touch process for capturing evidence of mid- to long term impact of its funding, capturing publications, follow on funding and real-world impact at 3- and 5-years post project points
- Encouraging proposals from allied health professionals
- Adding a panel member with social sciences/ qualitative research expertise to the Research Committee
- Exploring ways of telling stories about funded research, for example, capturing testimonies of patients involved in research through case studies



BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education & Research Trust. The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration, support, including the accreditation and sponsorship where necessary, for educational events reaching 357 healthcare professionals, significantly up from 254 last year and 300 the year before. Some face-to-face sessions, alongside online delivery were reinstated in hybrid sessions.

Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

Five Rheumatology Research group meetings were held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time. This meeting was renamed Bath Inflammation and Immunology Research Group.

The South West CTD & Vasculitis Meeting was held on 21 September 2021.

The Regional South-West Osteoporosis Meeting was held on 16 November 2021.

The South West Axial Spondyloarthritis Group was held on 23 November 2021.

The Primary Care Rheumatology Update afternoon was held on 29 March 2022.

Qualitative feedback collected from some of the sessions showed that participants rated talks either 'excellent' or 'good' with most comments finding the training "helpful" and a useful update, eg "a good summary reminding me of salient topics" and "brilliant afternoon with varied and interesting presentations". Participants had plenty of learning points to share with colleagues.

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.



The Patient and Public Engagement Programme

Our vision was restated during the year 'to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment'. With twin aims of:

1. Patients have a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals
2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke since 2016, the programme has continuously evolved and developed around patient audience needs. It provides opportunities for them to connect, learn and share through a flexible and innovative mix of media.

Podcasts covering a range of rheumatology conditions, these now reach thousands of patients and their families, across the country (and beyond) heavily promoted on social media. Over the year Mel Brooke produced 15 new podcasts bringing the library to 35 and achieving an amazing 3,950 listens. New topics covered were Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis, self-management and wellbeing topics of fatigue, sleep and social prescribing.

Webinars were introduced for the first time, providing live events online that give patients access to consultants and experts' presentations and the opportunity to ask questions. 48 patients attended these first webinars.

Research - patients tell us they are keen to 'give back' and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. Over 2,600 patients were invited to

participate and 251 patients got involved in research during the year.

Patient Research Panel - 21 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year Patient centered culture We work hard to understand and accommodate patient needs and provide what is meaningful to them, through formative survey, feed back and involvement in the governance of BIRD. Two new cases studies were produced to tell patients' stories.

Impacts

8,826 podcast listens in the two-year period April 2020 to April 2022

76% of listeners to podcasts understood their condition better as result

85 % reported increased confidence to live with their condition

85% felt empowered to make decisions about their treatments

75% reported that hearing voices of clinicians and healthcare practitioners was reassuring

58% reported the podcasts a help to their mental health - they felt supported, less isolated and part of a community

Patients said:

'I learnt a great deal about my condition and about possible ways to help myself. I was able to recognise and adapt some of the wider potential impacts of life and health choices'

'The more we as patients understand about Psoriatic Arthritis, the more effectively we can manage our condition'

'All useful, especially identifying with fellow sufferers'

'Everything was really interesting, educational and inspirational'

'My main motivation to participate in research opportunities is to hopefully help future generations and the current understanding of rheumatic diseases.'



Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook advertising for the podcasts, with over 200,000 people getting the opportunity to see a BIRD advertisement for the podcasts.

Effort spent in seeking to attract grants from pharmaceutical companies for the Patient Engagement programme began to pay off, and resulted in £43,000 in grants and awards. This was largely due to the excellent performance of the podcasts and advertising them widely on social media, which attracted thousands of listeners.

In November 2021 BIRD was delighted to win the international Amgen UPLIFT Innovation Challenge worth \$25,000 for its development of digital support for patients. Other pharmaceutical funders were Eli Lilly and Company Ltd and UCB.

Further grants were awarded to the Patient and Public Engagement programme by the Champliss Charitable Trust, HealthWatch B&NES, Renishaw, The Saturday Hospital Fund, and the Siddons Charitable Trust.

Dr Ben Mulhearn ran the Palma half marathon and raised £1207 and a team of MBA students from the University of Bath raised £820 for BIRD's research funds.

The main achievements and performance of the charity in terms of public benefit

The total amount of grants awarded for research into rheumatic diseases was **£55,047**.

357 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

3,950 listens to podcasts for patients and 511 registered for newsletters. The total network reached via mailings and social media ad postings was estimated at almost 200,000 patients and members of the public.

76% of listeners to podcasts understood their condition better as result.

251 patients participated in research, and over 2,600 were invited to participate.

Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and Hospital.

Fundraising was greatly more than doubled, largely thanks to pharmaceutical grants but also thanks to the efforts of individuals.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefited from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.



Structure, governance and management of the charity

The governing body is the Council of Management made up of 9 trustees. The chair is Chris Johns. Council of Management meets quarterly.

Three committees report in to the Council of Management. These are the quarterly Finance Committee, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns and Linda Snelus; the biannual Research Committee, chaired by Professor Bernie Morley emeritus, members are Professor Rod Flower, Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr John Pauling, Dr Sarah Skeoch, Dr Paula Smith and Frank Sweeting; and the quarterly Education & Engagement Committee, chaired by Stephanie Lear, members are Dr Andrew Allard, Katie Burfitt, Judy Coles and Dr Patrick Ismond. All committees are supported by relevant contract staff in attendance.

Financial review

The financial position of the charity at 31 March 2022 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2022	2021
	£	£
Net income	117,107	172,928
Unrestricted Revenue Funds available for the general purposes of the charity	1,778,291	1,667,587
Designated Revenue Funds	21,513	14,666
Total Unrestricted Funds	1,799,804	1,682,253
Restricted Revenue Funds	19,701	20,145
Total Funds	1,819,505	1,702,398

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham, B1 2HB

CCLA Investment Management Ltd, COIF Charity Funds, Senator House, London

Royal London Asset Management, 55 Gracechurch Street, London

Solicitors

Stone King, 13 Queen Square, Bath, BA1 2HJ

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath, BA1 3RU

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.



BIRD's reserves policy is to

- Hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- Retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received and will encourage clinicians to undertake research and early stage career researchers. It will help thousands of patients to

understand their disease and treatment better and, with renewed focus, hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

Details of The Independent Examiner

Tom Case
Member of The Institute of Chartered Accountants in
England and Wales
20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY



Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP),

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- To prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 13-19.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016).



These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 20 September 2022.

Christopher Johns,
Chair



Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

I report to the Trustees on my examination of the financial statements of the charitable company on pages 13 to 19 for the year ended 31 March 2022 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 22.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 1, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- A.** Examine the financial statements of the charity under Section 145 of the Act;
- B.** Follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable

No material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

- Accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011
- The financial statements do not accord with those records; or the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination
- Have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:

A handwritten signature in black ink, appearing to read 'T. Case'.

Mr Tom Case, Independent Examiner

The Institute of Chartered Accountants in
England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

This report was signed on 20 September 2022.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

	SORP Ref	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Income & Endowments from:					
Donations & Legacies	A1	55,858	-	55,858	20,340
Charitable activities	A2	20,579	150	20,729	23,064
Investments	A4	47,199	-	47,199	49,315
Total income	A	123,636	150	123,786	92,719
Expenditure on:					
Charitable activities	B2	180,300	594	180,894	224,733
Total expenditure	B	180,300	594	180,894	224,733
Net gains on investments	B4	132,320	-	132,320	304,942
Net income for the year		75,656	(444)	75,212	172,928
Transfers between funds	C	-	-	-	-
Net income after transfers	A-B-C	75,656	(444)	75,212	172,928
Extraordinary items	D3	41,895	-	41,895	-
Net movement in funds		117,551	(444)	117,107	172,928
Reconciliation of funds:-					
Total funds brought forward	E	1,682,253	20,145	1,702,398	1,529,470
Total funds carried forward		1,799,804	19,701	1,819,505	1,702,398

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.

All activities derive from continuing operations.
The notes attached on pages 22 to 41 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Analysis of prior year total funds as required by paragraph 4.2 of the SORP.

	SORP REF	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £
Income & Endowments from:				
Donations & Legacies	A1	20,340	-	20,340
Charitable activities	A2	22,449	615	23,064
Investments	A4	49,315	-	49,315
Total income	A	92,104	615	92,719
Expenditure on:				
Charitable activities	B2	223,799	934	224,733
Total expenditure	B	223,799	934	224,733
Net gains on investments	B4	304,942	-	304,942
Net income for the year		173,247	(319)	172,928
Transfers between funds	C	2,085	(2,085)	-
Net income after transfers		175,332	(2,404)	172,928
Net movement in funds		175,332	(2,404)	172,928
Reconciliation of funds:-				
Total funds brought forward	E	1,506,921	22,549	1,529,470
Total funds carried forward		1,682,253	20,145	1,702,398

All activities derive from continuing operations.

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement.

The notes attached on pagesv form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Statement of Total Recognised Gains and Losses for the year ended 31 March 2022

	2022 £	2021 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(57,108)	(132,014)
	-	-
Income from operations before tax in the Statement of Financial Activities	(57,108)	(132,014)
Realised (losses)/gains on investments	(2,104)	16,967
Extraordinary items	41,895	-
Surplus as shown in the Income and Expenditure account	(17,317)	(115,047)
Unrealised (losses)/gains on investments	134,424	287,975
Net Movement in funds before taxation	117,107	172,928
	-	-
Funds generated in the year as shown on Statement of Financial Activities	117,107	172,928

Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use

	2022 £	2022 £
Funds generated in the year as detailed in the SOFA	117,107	172,928
Resources applied on functional fixed assets	-	(1,260)
	-	-
Net resources available to fund charitable activities	117,107	171,668

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use

Revenue accumulated funds	Unrestricted Funds 2022	Restricted Funds 2022	Total Funds 2022	Last year Total Funds 2021
	£	£	£	£
Accumulated funds brought forward	1,682,253	20,145	1,702,398	1,529,470
Recognised gains and losses before transfers	75,656	(444)	75,212	172,928
	1,757,909	19,701	1,777,610	1,702,398
Extraordinary items	41,895	-	41,895	-
Closing revenue funds	1,799,804	19,701	1,819,505	1,702,398

Designated revenue funds included within the unrestricted funds above

	Total Funds 2022	Last year Total Funds 2021
	£	£
At 1 April	14,666	14,595
Transfer (to)/from revenue accumulated funds	6,847	71
At 31 March	21,513	14,666

The purposes for which these funds have been designated are described in Note 22 to the accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Summary of funds

	Unrestricted and Designated Funds	Restricted Funds	Total Funds	Last Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Revenue accumulated funds	1,778,291	19,701	1,797,992	1,687,732
Revenue designated funds	21,513	-	21,513	14,666
Total funds	1,799,804	19,701	1,819,505	1,702,398

The notes attached on pages 22 to 41 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Income and Expenditure Account for the year ended 31 March 2022 as required by the Companies Act 2006

	2022	2021
	£	£
Income		
Income from operations	76,587	43,404
Realised gains/(losses) on investments	-	16,967
Investment income		
Income from investments, other than interest receivable	47,199	49,315
Gross income in the year before exceptional items	123,786	109,686
Gross income in the year including exceptional items	123,786	109,686
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	180,180	223,984
Depreciation and amortisation	276	329
Governance costs	438	420
Realised losses on the disposal of investments	2,104	-
Total expenditure in the year	182,998	224,733
Extraordinary items	41,895	-
Net income before tax in the financial year	(17,317)	(115,047)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(17,317)	(115,047)
Retained surplus for the financial year	(17,317)	(115,047)

All activities derive from continuing operations.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 22 to 41 form an integral part of these accounts.

Balance Sheet as at 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

	Note	SORP Ref	2022 £	2021 £
Fixed assets		A		
Tangible assets	11	A2	943	1,219
Investments held as fixed assets	12	A4	1,736,569	1,602,145
Total fixed assets			<u>1,737,512</u>	<u>1,603,364</u>
Current assets		B		
Debtors	14	B2	18,284	9,798
Cash at bank and in hand		B4	151,545	259,598
Total current assets			<u>169,829</u>	<u>269,396</u>
Creditors: amounts falling due within one year	15	C1	<u>(87,836)</u>	<u>(170,362)</u>
Net current assets			81,993	99,034
The total net assets of the charity			<u>1,819,505</u>	<u>1,702,398</u>
The total net assets of the charity are funded by the funds of the charity, as follows:-				
Restricted funds				
Restricted Revenue Funds	19	D2	19,701	20,145
			19,701	20,145
Unrestricted Funds				
Unrestricted Revenue Funds	19	D3	1,778,291	1,667,587
			1,778,291	1,667,587
Designated Funds				
Designated Revenue Funds	19	D3	21,513	14,666
			21,513	14,666
Total charity funds			<u>1,819,505</u>	<u>1,702,398</u>



The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 11.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

A handwritten signature in black ink, reading 'Jim Sherwin'.

Mr JT Sherwin

Trustee and Chair of Finance Committee

Approved by the board of trustees on 20 September 2022.

Bath Institute for Rheumatic Diseases
Supporting Arthritis Research in Bath



Registered Charity 1040650
01225 336363 BIRD@birdbath.org.uk

Bath Institute
Rheumatic Diseases



1. Accounting Policies

Policies Relating to the Production of the Accounts

Basis of Preparation and Accounting Convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainties about the charity's ability to continue as a going concern.

Risks and Future Assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition

Nature of Income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income Recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.



Income from Legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities.

Policies relating to expenditure on goods and services provided to the charity.

Recognition of Liabilities and Expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.



Tangible Fixed Assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery - 20 % reducing balance.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial Instruments Including Cash and Bank Balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes. Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law. There are no endowment funds.

2. Liability to Taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3. Winding up or Dissolution of the Charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4. Significance of Financial Instruments to the Charity's Position

There are no significant implications of financial instruments to the charity's financial position or performance.

5. Net Surplus Before Tax in the Financial Year

The net surplus before tax in the financial year is stated after charging. Depreciation of owned fixed assets:

2022 = £276

2021 = £329



6. Investment Gains

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Realised gains/(losses)				
Listed investments	(2,104)	-	(2,104)	16,967
Total realised gains/(losses)	(2,104)	-	(2,104)	16,967
Unrealised gains /(losses) and writing down of carrying values				
Listed investments - Unrealised	134,424	-	134,424	287,975
Total unrealised gains/(losses) etc	134,424	-	134,424	287,975
Total realised and unrealised gains	132,320	-	132,320	304,942

All gains and losses in the prior year was unrestricted.

Prior Year:-

	Prior Year Unrestricted Funds 2021	Prior Year Restricted Funds 2021	Prior Year Total Funds 2021
	£	£	£
Realised gains/(losses)			
Listed investments	16,967	-	16,967
Total realised gains/(losses)	16,967	-	16,967
Unrealised gains /(losses) and writing down of carrying values			
Listed investments - Unrealised	287,975	-	287,975
Total unrealised gains/(losses) etc	287,975	-	287,975
Total realised and unrealised gains	304,942	-	304,942



7. Extraordinary items - analysed by fund

		2022	2021
		£	£
Unrestricted funds	(41,895)		
Restricted funds	-		
Total extraordinary items		(41,895)	-
		(41,895)	-

This item comprises £23,085 of a cancelled grant from previous years and £18,810 of an underspend from the funded clinical lectureship finishing earlier than awarded, due to promotion.

8. Staff costs and emoluments

Labour costs	2022	2021
	£	£
Gross salaries, labour and related costs	99,490	111,081
	99,490	111,081

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

9. Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.



10. Trustee's expenses

No trustee expenses were incurred, either in the current or prior year.

11. Tangible fixed assets

No trustee expenses were incurred, either in the current or prior year.

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2021	-	11,940	-	11,940
Additions	-	-	-	-
At 31 March 2022	-	11,940	-	11,940
Depreciation				
At 1 April 2021	-	10,721	-	10,721
Charge for the year	-	276	-	276
At 31 March 2022	-	10,997	-	10,997
Net book value				
At 31 March 2022	-	943	-	943
At 31 March 2021	-	1,219	-	1,219

12. Investments Held as Fixed Assets

	Investments in subsidiaries	Listed investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2021	2	1,602,143	-	1,602,145
Revaluation at 31 March 2022	-	134,424	-	134,424
At 31 March 2022	2	1,736,567	-	1,736,569
Analysis between fair value and historical cost				
Investments as above held at fair value	2	1,736,567	-	1,736,569



13. Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the seven years ending 31st March 2022.

A summary of the unaudited financial statements of the subsidiary is :-

	2022 £	2021 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)
Profit and Loss		
Net profit for the year before tax	-	-
Net profit for the year after tax and Gift Aid	-	-

Funds retained within charitable subsidiaries

	2022 £	2021 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	-	-



14. Debtors

	2022	2021
	£	£
Trade debtors	6,812	6,851
Prepayments and accrued income	11,472	2,947
	18,284	9,798

15. Creditors: amounts falling due within one year

	2022	2021
	£	£
Trade creditors	29,191	29,859
Accruals	600	600
Other creditors	58,045	139,903
	87,836	170,362

16. Income and Expenditure account summary

	2022	2021
	£	£
At 1 April 2021	1,414,423	1,529,470
Surplus after tax for the year	(17,317)	(115,047)
At 31 March 2022	1,397,106	1,414,423

17. No related party transactions

There were no transactions with related parties in the year.



18. Particulars of How Particular Funds are Represented by Assets and Liabilities

At 31 March 2022	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Tangible Fixed Assets	943	-	-	943
Investments at valuation:-				
Fixed asset investments	1,736,569	-	-	1,736,569
Current Assets	128,615	21,513	19,701	169,829
Current Liabilities	(87,836)	-	-	(87,836)
	1,778,291	21,513	19,701	1,819,505
At 1 April 2021	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Tangible Fixed Assets	1,219	-	-	1,219
Investments at valuation:-				
Fixed asset investments	1,602,145	-	-	1,602,145
Current Assets	234,585	14,666	20,145	269,396
Current Liabilities	(170,362)	-	-	(170,362)
	1,667,587	14,666	20,145	1,702,398



19. Change in total funds over the year as shown in Note 18, analysed by individual funds

	Funds brought forward from 2021	Movement in funds in 2022	Transfers between funds in 2022	Funds carried forward to 2023
	£	See Note 20 £	See Note 21 £	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,667,587	117,551	(6,847)	1,778,291
Designated Revenue Funds	14,666	-	6,847	21,513
Total unrestricted and designated funds	1,682,253	117,551	-	1,799,804
Restricted funds:-				
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - CRPS Network UK	1,691	(594)	-	1,097
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Arthritis Grand Challenge	67	-	-	67
Restricted - Metabolic Bone Disease	3,121	150	-	3,121
Total restricted funds	20,145	(444)	-	19,701
Total charity funds	1,702,398	117,107	-	1,819,505



20. Analysis of movements in funds over the year as shown in Note 19

			Other	
	Income 2022 £	Expenditure 2022 £	Gains & Losses 2022 £	Movement in funds 2022 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	123,636	(180,300)	174,215	117,551
Restricted funds:-				
Restricted - CRPS Network UK		(594)	-	(594)
Restricted - Metabolic Bone Disease	150	-	-	150
	123,786	(180,894)	174,215	117,107

21. Details of transfers between

The transfers shown in note 18 above are:-	2022 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	(6,847)
To/(from) Designated Revenue Funds	6,847
To/(from) Restricted Revenue Funds	-
Net transfers	-

22. The purposes for which the funds

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds

Funds specific for this purpose.

Restricted Revenue Funds

Funds specific for this purpose.



23. Ultimate controlling party

The charity is under the control of its legal members. Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

24. Donations, Grants and Legacies

	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total Funds 2021
	£	£	£	£
Donations and gifts from individuals				
Donations	55,858	-	55,858	19,783
Total donations and gifts from individuals	55,858	-	55,858	19,783
	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total Funds 202
	£	£	£	£
Legacies receivable				
Legacies receivable	-	-	-	557
Total legacies receivable	-	-	-	557
Total Donations, Grants and Legacies	55,858	-	55,858	20,340

A1

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

25. Income from charitable activities - Trading Activities

Current year	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total funds 2021
	£	£	£	£
Primary purpose and ancillary trading				
Education income	625	-	625	341
Other and recharged income	3,465	150	3,615	675
Service charges - BGPRT	11,723	-	11,723	17,975
Service charges - BRIT PACT	4,766	-	4,766	4,073
Total Primary purpose and ancillary trading	20,579	150	20,729	23,064

Not all the trading activities in the prior year were unrestricted.

	Prior Year Unrestricted Funds 2021	Prior Year Restricted Funds 2021	Prior Year Total Funds 2021
Prior year	£	£	£
Primary purpose and ancillary trading			
Other and recharged income	60	615	675
Total Primary purpose and ancillary trading	22,449	615	23,064

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

26. Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Total income from charitable trading	20,579	150	20,729	23,064
Total from charitable activities	A2 20,579	150	20,729	23,064

Not all the income in the prior year was unrestricted.

Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year 2021	Prior Year 2021	Prior Year 2021
	£	£	£
Total income from charitable trading	22,449	615	23,064
Income from funders	-	-	-
	22,449	615	23,064

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

27. Investment income

	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total funds 2021
	£	£	£	£
Dividend Income	47,199	-	47,199	49,315
Total investment income	A4 47,199	-	47,199	49,315

28. Expenditure on charitable activities - Direct spending

Current year	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total Funds 2021
	£	£	£	£
Labour costs - charitable activities	99,490	-	99,490	111,081
Education costs	1,042	-	1,042	-
PPE Project costs	4,709	-	4,709	4,189
Travel and conferences	-	-	-	150
Total direct spending	B2a 105,241	-	105,241	115,420

Not all the income in the prior year was unrestricted.

Prior year	Prior Year 2021	Prior Year 2021	Prior Year 2021
	£	£	£
PPE Project costs	4,189	-	4,189
Total direct spending	B2a 115,420	-	115,420



29. Expenditure on charitable activities - grant funding of activities

<i>Current year</i>		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Grants made to individuals		55,047	-	55,047	78,688
Grant underspends from prior years		-	-	-	-
Total grantmaking costs	B2c	55,047	-	55,047	78,688

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

30. Support costs for charitable activities

Current Year	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Premises Expenses				
Rent	5,550	-	5,550	5,100
Administrative overheads				
Telephone, fax and internet	720	-	720	720
Stationery and printing	409	-	409	544
Marketing and promotion	1,174	-	1,174	3,078
Registration and licensing	657	-	657	653
IT support costs	1,288	-	1,288	1,237
Sundry expenses	168	-	168	28
Recharged expenses	4,119	594	4,713	1,715
Insurance	439	-	439	435
Hospitality	57	-	57	10
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	3,060	-	3,060	2,840
Other legal and professional	1,497	-	1,497	9,766
Financial costs				
Bank charges	160	-	160	157
Investment management costs	-	-	-	3,593
Depreciation & Amortisation in total for the period	276	-	276	329
Support costs before reallocation	19,574	594	20,168	30,205
Total support costs - Current Year	19,574	594	20,168	30,205

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Support costs for charitable activities cont.

Prior Year

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2021 £
Recharged expenses	781	934	1,715
Support costs before reallocation	29,271	934	30,205
Total support costs - Prior Year	29,271	934	30,205

31. Other Expenditure - Governance costs

Current Year

	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Fund 2022 £	Prior Year Total Funds 2021 £
Independent Examiner's fees	438	-	438	420
Trustees' expenses	-	-	-	-
Total Governance costs	438	-	438	420

All the expenditure in the prior year was unrestricted.

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

32. Total Charitable expenditure

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Total direct spending	B2a	105,241	-	105,241	115,420
Total grantmaking costs	B2c	55,047	-	55,047	78,688
Total support costs	B2d	19,574	594	20,168	30,205
Total Governance costs	B2e	438	-	438	420
Total charitable expenditure	B2	180,300	594	180,894	224,733

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2021	2021	2021
		£	£	£
Total direct spending	B2a	115,420	-	115,420
Total grantmaking costs	B2c	78,688	-	78,688
Total support costs	B2d	29,271	934	30,205
Total Governance costs	B2e	420	-	420
Total charitable expenditure	B2	223,799	934	224,733



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Annual Report and Accounts

31 March 2022